日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies

MTAP缺失在癌基因驱动的非小细胞肺癌中很常见,并可能使肿瘤对PRMT5抑制剂和靶向治疗联合治疗敏感。

Aldea, M; Lenahan, S; Locquet, M-A; Liao, L; Gasparro, M; Gokhale, P C; Ghigna, M-R; Ionescu, D N; Odintsov, I; Ngo, K; Wang, X; Aziz, S; Pecci, F; Garbo, E; Ivanova, E; Nakazawa, S; Kulesza, J; Tsai, J A; Zullo, L; Lee, J; Zielinska, M; Simon, S; Han, D; Marinello, A; Li, G; Rossato de Almeida, G; Huang, J; Paoloni, F; Gariazzo, E; Santo, V; Remon, J; Marks, J A; LoPiccolo, J; Florez, N; Nishino, M; Ricciuti, B; Luo, J; Barbie, D A; Planchard, D; Rotow, J K; Barlesi, F; Graf, R P; Feng, W W; Besse, B; Paweletz, C; Sholl, L; Shaw, A T; Jänne, P A

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab

接受帕博利珠单抗治疗的非小细胞肺癌患者的预后和治疗

Rousseau, Adrien; Foulon, Stéphanie; Planchard, David; Remon, Jordi; Barlesi, Fabrice; Lavaud, Pernelle; Frelaut, Maxime; Aldea, Mihaela; Parisi, Claudia; Gazzah, Anas; Le Pechoux, Cécile; Botticella, Angela; Levy, Antonin; Simon-Tillaux, Noémie; Michiels, Stefan; Besse, Benjamin

First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

EGFR突变转移性非小细胞肺癌的一线治疗及治疗顺序:哪种治疗方案适合哪位患者?

Abdayem, Pamela; Parisi, Claudia; Planchard, David

Global advances and future directions in lung cancer care: expert consensus and strategic priorities

全球肺癌治疗进展及未来方向:专家共识和战略重点

Meyer, M-L; Peters, S; Jänne, P A; Mok, T S; Bunn, P A; Abdel Karim, N; Altorki, N K; Arrieta, O; Bar, J; Cappuzzo, F; Carbone, D; Dacic, S; Diehn, M; Dziadziuszko, R; Felip, E; Flores, R; Florez, N; Forde, P M; Gainor, J F; Gray, J E; Gros, L; Halmos, B; Henschke, C I; Herbst, R; Heymach, J V; Kelly, K; Kris, M G; Leighl, N B; Mathias, C; Marron, T U; Mulshine, J L; Naidoo, J; Osarogiagbon, R; Passaro, A; Peled, N; Planchard, D; Politi, K; Popat, S; Pyenson, B; Reckamp, K L; Ren, S H; Riely, G J; Rolfo, C; Rudin, C M; Sen, T; Shields, M D; Singh, H; Skoulidis, F; Solomon, B J; Stahel, R; Stiles, B M; Syrigos, K; Yang, J C-H; Yang, P-C; Wolf, A; Wozniak, A J; Waqar, S N; Wakelee, H; Hirsch, F R

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF(V600E)-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison

恩科拉非尼联合比美替尼与达拉非尼联合曲美替尼一线治疗BRAF(V600E)突变转移性非小细胞肺癌患者的疗效比较:一项匹配调整的间接治疗比较研究

Planchard, D; Mazières, J; Grouin, J M; Le Reun, C; Luttenauer, H; Boussahoua, M; Macabeo, B

Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report

肠道菌群失调作为非小细胞肺癌免疫治疗2年后是否继续治疗的潜在指导:简要报告

Bonato, Adele; Parisi, Claudia; Cascetta, Priscilla; Reni, Anna; Meyer, May-Lucie; Riudavets, Mariona; Planchard, David; Besse, Benjamin; Remon, Jordi; Facchinetti, Francesco; Belluomini, Lorenzo; Derosa, Lisa; Barlesi, Fabrice

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors

Beamion PANTUMOR-1:zongertinib治疗HER2过表达/扩增或HER2突变实体瘤的II期试验的理论依据和设计

Schram, Alison M; Park, John J; Italiano, Antoine; Kitano, Shigehisa; Guo, Ye; Li, Jin; Bedard, Philippe L; van Marcke, Cedric; Ko, Ryo; Lunger, Lukas; Klotz, Daniel M; Hussain, Jo; Maier, Daniela; Erzen, Damijan; Planchard, David; Prenen, Hans; Clay, Timothy D; Park, Joon O; Kim, Hyung-Don; Hernando-Calvo, Alberto; Maruki, Yuta; Ponz-Sarvise, Mariano; Dumbrava, Ecaterina

The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer

阿联酋首个关于早期和晚期非小细胞肺癌诊断和治疗的专家共识建议

Al Shamsi, Humaid; Abdelwahed, Nadia; Jaafar, Hassan; Ghazal, Hassan; Kourie, Hampig Raphael; Naim, Nabih; Otsman, Sonia; Bennini, Nouri; Dawoud, Emad; Trad, Diaeddine; Mukherjee, Deborah; Rafii, Saeed; Ramanathan, Dorai; Tirmazy, Syed Hamad; Elshourbagy, Dalia M; Hamza, Dina; Azribi, Fathi; El Khoury, Maroun; Planchard, David; Peters, Solange

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

作者更正:CTLA4阻断可消除KEAP1/STK11相关的PD-(L)1抑制剂耐药性

Skoulidis, Ferdinandos; Araujo, Haniel A; Do, Minh Truong; Qian, Yu; Sun, Xin; Cobo, Ana Galan; Le, John T; Montesion, Meagan; Palmer, Rachael; Jahchan, Nadine; Juan, Joseph M; Min, Chengyin; Yu, Yi; Pan, Xuewen; Arbour, Kathryn C; Vokes, Natalie; Schmidt, Stephanie T; Molkentine, David; Owen, Dwight H; Memmott, Regan; Patil, Pradnya D; Marmarelis, Melina E; Awad, Mark M; Murray, Joseph C; Hellyer, Jessica A; Gainor, Justin F; Dimou, Anastasios; Bestvina, Christine M; Shu, Catherine A; Riess, Jonathan W; Blakely, Collin M; Pecot, Chad V; Mezquita, Laura; Tabbó, Fabrizio; Scheffler, Matthias; Digumarthy, Subba; Mooradian, Meghan J; Sacher, Adrian G; Lau, Sally C M; Saltos, Andreas N; Rotow, Julia; Johnson, Rocio Perez; Liu, Corinne; Stewart, Tyler; Goldberg, Sarah B; Killam, Jonathan; Walther, Zenta; Schalper, Kurt; Davies, Kurtis D; Woodcock, Mark G; Anagnostou, Valsamo; Marrone, Kristen A; Forde, Patrick M; Ricciuti, Biagio; Venkatraman, Deepti; Van Allen, Eliezer M; Cummings, Amy L; Goldman, Jonathan W; Shaish, Hiram; Kier, Melanie; Katz, Sharyn; Aggarwal, Charu; Ni, Ying; Azok, Joseph T; Segal, Jeremy; Ritterhouse, Lauren; Neal, Joel W; Lacroix, Ludovic; Elamin, Yasir Y; Negrao, Marcelo V; Le, Xiuning; Lam, Vincent K; Lewis, Whitney E; Kemp, Haley N; Carter, Brett; Roth, Jack A; Swisher, Stephen; Lee, Richard; Zhou, Teng; Poteete, Alissa; Kong, Yifan; Takehara, Tomohiro; Paula, Alvaro Guimaraes; Parra Cuentas, Edwin R; Behrens, Carmen; Wistuba, Ignacio I; Zhang, Jianjun; Blumenschein, George R; Gay, Carl; Byers, Lauren A; Gibbons, Don L; Tsao, Anne; Lee, J Jack; Bivona, Trever G; Camidge, D Ross; Gray, Jhannelle E; Leighl, Natasha B; Levy, Benjamin; Brahmer, Julie R; Garassino, Marina C; Gandara, David R; Garon, Edward B; Rizvi, Naiyer A; Scagliotti, Giorgio Vittorio; Wolf, Jürgen; Planchard, David; Besse, Benjamin; Herbst, Roy S; Wakelee, Heather A; Pennell, Nathan A; Shaw, Alice T; Jänne, Pasi A; Carbone, David P; Hellmann, Matthew D; Rudin, Charles M; Albacker, Lee; Mann, Helen; Zhu, Zhou; Lai, Zhongwu; Stewart, Ross; Peters, Solange; Johnson, Melissa L; Wong, Kwok K; Huang, Alan; Winslow, Monte M; Rosen, Michael J; Winters, Ian P; Papadimitrakopoulou, Vassiliki A; Cascone, Tina; Jewsbury, Philip; Heymach, John V

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

达托泊单抗德鲁西替康治疗具有可靶向基因组改变的晚期或转移性非小细胞肺癌:来自 II 期 TROPION-Lung05 研究的结果

Sands, Jacob; Ahn, Myung-Ju; Lisberg, Aaron; Cho, Byoung Chul; Blumenschein, George Jr; Shum, Elaine; Pons Tostivint, Elvire; Goto, Yasushi; Yoh, Kiyotaka; Heist, Rebecca; Shimizu, Junichi; Lee, Jong-Seok; Baas, Paul; Planchard, David; Pérol, Maurice; Felip, Enriqueta; Su, Wu-Chou; Zebger-Gong, Hong; Lan, Lan; Liu, Chelsea; Howarth, Paul; Chiaverelli, Rachel; Paz-Ares, Luis